Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: rituximab
DATE: 26/07/2017
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
